Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362489788> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4362489788 abstract "<div>Abstract<p>The second-generation antiandrogen, enzalutamide, is approved for castrate-resistant prostate cancer (CRPC) and targets androgen receptor (AR) activity in CRPC. Despite initial clinical activity, acquired resistance to enzalutamide arises rapidly and most patients develop terminal disease. Previous work has established Stat5 as a potent inducer of prostate cancer growth. Here, we investigated the significance of Jak2–Stat5 signaling in resistance of prostate cancer to enzalutamide. The levels of Jak2 and Stat5 mRNA, proteins and activation were evaluated in prostate cancer cells, xenograft tumors, and clinical prostate cancers before and after enzalutamide therapy. Jak2 and Stat5 were suppressed by genetic knockdown using lentiviral shRNA or pharmacologic inhibitors. Responsiveness of primary and enzalutamide-resistant prostate cancer to pharmacologic inhibitors of Jak2–Stat5 signaling was assessed <i>in vivo</i> in mice bearing prostate cancer xenograft tumors. Patient-derived prostate cancers were tested for responsiveness to Stat5 blockade as second-line treatment after enzalutamide <i>ex vivo</i> in tumor explant cultures. Enzalutamide-liganded AR induces sustained Jak2–Stat5 phosphorylation in prostate cancer leading to the formation of a positive feed-forward loop, where activated Stat5, in turn, induces Jak2 mRNA and protein levels contributing to further Jak2 activation. Mechanistically, enzalutamide-liganded AR induced Jak2 phosphorylation through a process involving Jak2-specific phosphatases. Stat5 promoted prostate cancer growth during enzalutamide treatment. Jak2–Stat5 inhibition induced death of prostate cancer cells and patient-derived prostate cancers surviving enzalutamide treatment and blocked enzalutamide-resistant tumor growth in mice. This work introduces a novel concept of a pivotal role of hyperactivated Jak2–Stat5 signaling in enzalutamide-resistant prostate cancer, which is readily targetable by Jak2 inhibitors in clinical development.</p></div>" @default.
- W4362489788 created "2023-04-05" @default.
- W4362489788 creator A5006909847 @default.
- W4362489788 creator A5012135806 @default.
- W4362489788 creator A5016680184 @default.
- W4362489788 creator A5030870196 @default.
- W4362489788 creator A5040800642 @default.
- W4362489788 creator A5044298637 @default.
- W4362489788 creator A5048251224 @default.
- W4362489788 creator A5051433085 @default.
- W4362489788 creator A5054896904 @default.
- W4362489788 creator A5055202049 @default.
- W4362489788 creator A5055216359 @default.
- W4362489788 creator A5057146540 @default.
- W4362489788 creator A5072652868 @default.
- W4362489788 creator A5086080626 @default.
- W4362489788 date "2023-04-03" @default.
- W4362489788 modified "2023-09-25" @default.
- W4362489788 title "Data from Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors" @default.
- W4362489788 doi "https://doi.org/10.1158/1535-7163.c.6542868" @default.
- W4362489788 hasPublicationYear "2023" @default.
- W4362489788 type Work @default.
- W4362489788 citedByCount "0" @default.
- W4362489788 crossrefType "posted-content" @default.
- W4362489788 hasAuthorship W4362489788A5006909847 @default.
- W4362489788 hasAuthorship W4362489788A5012135806 @default.
- W4362489788 hasAuthorship W4362489788A5016680184 @default.
- W4362489788 hasAuthorship W4362489788A5030870196 @default.
- W4362489788 hasAuthorship W4362489788A5040800642 @default.
- W4362489788 hasAuthorship W4362489788A5044298637 @default.
- W4362489788 hasAuthorship W4362489788A5048251224 @default.
- W4362489788 hasAuthorship W4362489788A5051433085 @default.
- W4362489788 hasAuthorship W4362489788A5054896904 @default.
- W4362489788 hasAuthorship W4362489788A5055202049 @default.
- W4362489788 hasAuthorship W4362489788A5055216359 @default.
- W4362489788 hasAuthorship W4362489788A5057146540 @default.
- W4362489788 hasAuthorship W4362489788A5072652868 @default.
- W4362489788 hasAuthorship W4362489788A5086080626 @default.
- W4362489788 hasConcept C121608353 @default.
- W4362489788 hasConcept C126322002 @default.
- W4362489788 hasConcept C170493617 @default.
- W4362489788 hasConcept C2776235491 @default.
- W4362489788 hasConcept C2776551883 @default.
- W4362489788 hasConcept C2779391668 @default.
- W4362489788 hasConcept C2780192828 @default.
- W4362489788 hasConcept C502942594 @default.
- W4362489788 hasConcept C61367390 @default.
- W4362489788 hasConcept C71924100 @default.
- W4362489788 hasConceptScore W4362489788C121608353 @default.
- W4362489788 hasConceptScore W4362489788C126322002 @default.
- W4362489788 hasConceptScore W4362489788C170493617 @default.
- W4362489788 hasConceptScore W4362489788C2776235491 @default.
- W4362489788 hasConceptScore W4362489788C2776551883 @default.
- W4362489788 hasConceptScore W4362489788C2779391668 @default.
- W4362489788 hasConceptScore W4362489788C2780192828 @default.
- W4362489788 hasConceptScore W4362489788C502942594 @default.
- W4362489788 hasConceptScore W4362489788C61367390 @default.
- W4362489788 hasConceptScore W4362489788C71924100 @default.
- W4362489788 hasLocation W43624897881 @default.
- W4362489788 hasOpenAccess W4362489788 @default.
- W4362489788 hasPrimaryLocation W43624897881 @default.
- W4362489788 hasRelatedWork W2177175549 @default.
- W4362489788 hasRelatedWork W2806156214 @default.
- W4362489788 hasRelatedWork W2927728931 @default.
- W4362489788 hasRelatedWork W3044054345 @default.
- W4362489788 hasRelatedWork W3135324733 @default.
- W4362489788 hasRelatedWork W3155718207 @default.
- W4362489788 hasRelatedWork W4361817127 @default.
- W4362489788 hasRelatedWork W4361823263 @default.
- W4362489788 hasRelatedWork W4361849260 @default.
- W4362489788 hasRelatedWork W4361849348 @default.
- W4362489788 isParatext "false" @default.
- W4362489788 isRetracted "false" @default.
- W4362489788 workType "article" @default.